boring trade, page-13

Our ANDA is noticed and the last piece in the puzzle is in play, the "PRE APPROVAL INSPECTION", so all we wait on, imo of course, is the usual slow to move and incapable FDA to pass things in a timely fashion.

ST, almost at a minimum ACL will be earning $30m profit a year with our generic taking 50% market share, even if we only added a 10X PE that gives us a market cap of $300m, or $1,57 per share. This is at the lower end of the scale too!!

A 15X PE would give a $2.35 share price and we are looking at HA-Irinotecan to add some value on top of all that!! I wont be selling upon approval either and I still believe we will see around a 3 day re-rate of the share price also, as seen on TV when a stock makes a company changing announcement:))